At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
APC148 and Placebodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A First-in-human, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of APC148 in Healthy Adults
In Brief
A Phase 1 clinical trial evaluating APC148 and Placebo for Healthy Subjects. Completed, enrolled 46 participants across 1 site.
Detailed Summary
The purpose of this first-in-human trial is to investigate the safety, tolerability, and pharmacokinetics of APC148 after intravenous (IV) infusion of single ascending doses in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Subjects
CountriesSweden
CollaboratorsCTC Clinical Trial Consultants AB
Timeline
Phase 1CompletedFinished
20252026
First PostedApr 2024
Enrollment StartSep 2024
Primary CompletionMar 2025
TodayJul 2026
First PostedApr 11, 2024
Enrollment StartSep 2, 2024
Primary CompletionMar 10, 2025
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.2 years ago
Interventions
APC148 and Placebodrug
IV infusion